Drug | Site | Year | n | PD3+ | Without PCR-correction | With PCR-correction | ||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Excluded/loss | LCF | LPF | ACPR | Cure rate (KM) | Excluded/loss | LCF | LPF | ACPR | Cure rate (KM) | |||||||
n (%) | n (%) | n (%) | n (%) | n (%) | % | (95 % CI) | n (%) | n (%) | n (%) | n (%) | (%) | (95 % CI) | ||||
AS + SP | Al-Udayn | 2010 | 85 | 0 (0) | 2 (2.4) | 0 (0) | 0 (0) | 83 (100) | 100 | (95.7–100) | 2 (2.4) | 0 (0) | 0 (0) | 83 (100) | 100 | (95.7–100) |
AS + SP | Sharas | 2010 | 93 | 0 (0) | 11 (11.8) | 0 (0) | 0 (0) | 82 (100) | 100 | (95.6–100) | 11 (11.8) | 0 (0) | 0 (0) | 82 (100) | 100 | (95.6–100) |
AS + SP | Tur Bani Qa’is | 2010 | 95 | 0 (0) | 12 (13.7) | 1 (1.2) | 1(1.2) | 81 (97.6) | 97.6 | (91.8–99.4) | 14(14.7) | 0 (0) | 0 (0) | 81 (100) | 100 | (95.9–100) |
AS + SP | Al-Qaflah | 2011 | 90 | 0 (0) | 6 (6.7) | 0 (0) | 0 (0) | 84 (100) | 100 | (95.7–100) | 6 (6.7) | 0 (0) | 0 (0) | 84 (100) | 100 | (95.7–100) |
AS + SP | Bajil | 2013 | 102 | 0 (0) | 3 (2.9) | 1 (1) | 2 (2) | 96 (97) | 96 | (89.6–98.5) | 4 (3.9) | 2 (2) | 0 (0) | 96 (98) | 98 | (92.2–99.5) |
AL | Bajil | 2009 | 80 | 0 (0) | 6 (7.5) | 0 (0) | 0 (0) | 74 (100) | 100 | (95.1–100) | 6 (7.5) | 0 (0) | 0 (0) | 74 (100) | 100 | (95.1–100) |
AL | Jabal-Al-Sharq | 2010 | 95 | 1 (1.1) | 5 (5.3) | 0 (0) | 2 (2.2) | 88 (97.8) | 97.8 | (92.2–99.7) | 7 (7.4) | 0 (0) | 0 (0) | 88 (100) | 100 | (95.9–100) |
AL | Tur Bani Qa’is | 2013 | 93 | 0 (0) | 5 (5.4) | 5 (5.7) | 0 (0) | 83 (94.3) | 94.3 | (87.2–98.1) | 10 (10.8) | 0 (0) | 0 (0) | 83 (100) | 100 | (95.7–100) |